Xencor Inc
XNCRNasdaq
$17.47
↑ +16.9%Jul 17 close · end-of-day
Price
1Y↑ +97.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$1.4B
P/E
—
P/S
13.5
P/B
2.5
EV/EBITDA
—
PEG
—
FCF Yield
-14.4%
Dividend Yield
—
Revenue (TTM)
$97.4M
Net Income (TTM)
-$172.4M
Free Cash Flow (TTM)
-$188.8M
Gross Margin
—
Operating Margin
-217.9%
Net Margin
-177.1%
ROE
-33.4%
ROIC
-27.5%
Debt / Equity
0.2
Net Cash
-$94.4M
Return 1Y
+92.6%
Company profile
Xencor, Inc. focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma.
- CEO
- Bassil I. Dahiyat
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 280
- Headquarters
- California
- Website
- xencor.com
Management & directors
- Cornelissen Bart JanSR. VICE PRESIDENT & CFO
- Dahiyat Bassil IPRESIDENT & CEO
- Desjarlais John RSR. VICE PRESIDENT & CSO
- Eckert CeliaSVP, GENERAL COUNSEL
Roles derived from SEC Form 4 filings.
Earnings
XNCR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$4.5M↓ -86.2%
Diluted EPS-$1.71↑ +159.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $122.7M | $275.1M | $164.6M | $174.6M | $110.5M | $125.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$76.8M | $43.8M | -$82.5M | -$132.4M | -$178.4M | -$177.5M |
| Net income | -$69.3M | $82.6M | -$55.2M | -$133.1M | -$232.6M | -$91.9M |
| Diluted EPS | -$1.21 | $1.37 | -$0.93 | -$2.20 | -$3.58 | -$1.24 |
| Operating cash flow | -$5.0M | -$16.9M | $24.5M | -$77.9M | -$202.2M | -$135.1M |
| Free cash flow | -$15.5M | -$30.2M | -$14.0M | -$96.4M | -$208.3M | -$138.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -62.6% | 15.9% | -50.1% | -75.8% | -161.5% | -141.4% |
| Net margin | -56.5% | 30.0% | -33.5% | -76.2% | -210.5% | -73.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.9M | $17.8M | $52.8M | $32.7M | $43.6M | $21.0M | $28.2M | $4.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$55.4M | -$55.2M | -$13.2M | -$43.2M | -$33.2M | -$47.5M | -$53.6M | -$77.9M |
| Net income | -$67.3M | -$46.3M | -$45.6M | -$48.4M | -$30.8M | -$6.0M | -$6.7M | -$128.9M |
| Diluted EPS | -$1.09 | -$0.72 | -$0.57 | -$0.66 | -$0.41 | -$0.08 | -$0.09 | -$1.71 |
| Operating cash flow | -$67.3M | -$28.1M | -$49.8M | -$16.2M | -$36.4M | -$30.8M | -$51.7M | -$67.6M |
| Free cash flow | -$70.4M | -$29.4M | -$51.5M | -$17.7M | -$36.8M | -$31.0M | -$52.9M | -$68.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -231.6% | -310.2% | -25.0% | -131.9% | -76.1% | -226.3% | -189.9% | -1724.1% |
| Net margin | -281.7% | -260.1% | -86.3% | -147.9% | -70.7% | -28.7% | -23.6% | -2854.7% |
Company news
Jul 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Feigal Ellen | Sale | 6,843 | $13.06 | $89,369.58 | filing |
| 2026-06-16 | Feigal Ellen | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | GORMAN KEVIN CHARLES | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | GUSTAFSON KURT A | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | Klencke Barbara | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | Montgomery Alan Bruce | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | RANIERI RICHARD J | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | Deshaies Raymond Joseph | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-16 | SIMPSON TODD E | Award | 10,302 | $0.00 | $0.00 | filing |
| 2026-06-15 | GORMAN KEVIN CHARLES | Sale | 7,527 | $12.31 | $92,657.37 | filing |
| 2026-06-15 | GUSTAFSON KURT A | Sale | 5,474 | $12.31 | $67,384.94 | filing |
| 2026-06-15 | RANIERI RICHARD J | Sale | 5,474 | $12.31 | $67,384.94 | filing |
| 2026-06-15 | Montgomery Alan Bruce | Sale | 5,064 | $12.31 | $62,337.84 | filing |
| 2026-04-10 | Cornelissen Bart Jan· SR. VICE PRESIDENT & CFO | Sale | 3,499 | $12.29 | $42,990.46 | filing |
| 2026-03-06 | Dahiyat Bassil I· PRESIDENT & CEO | Sale | 6,606 | $11.02 | $72,796.14 | filing |
| 2026-03-06 | Desjarlais John R· SR. VICE PRESIDENT & CSO | Sale | 2,502 | $11.02 | $27,571.29 | filing |
| 2026-03-06 | Eckert Celia· SVP, GENERAL COUNSEL | Sale | 1,767 | $11.02 | $19,471.81 | filing |
| 2026-03-05 | Dahiyat Bassil I· PRESIDENT & CEO | Sale | 14,870 | $11.25 | $167,220.59 | filing |
| 2026-03-05 | Desjarlais John R· SR. VICE PRESIDENT & CSO | Sale | 4,118 | $11.25 | $46,308.97 | filing |
| 2026-03-05 | Eckert Celia· SVP, GENERAL COUNSEL | Sale | 3,244 | $11.25 | $36,480.40 | filing |
| 2026-03-05 | Cornelissen Bart Jan· SR. VICE PRESIDENT & CFO | Sale | 2,517 | $11.25 | $28,304.92 | filing |
| 2026-03-03 | Dahiyat Bassil I· PRESIDENT & CEO | Sale | 6,758 | $11.90 | $80,387.09 | filing |
| 2026-03-03 | Desjarlais John R· SR. VICE PRESIDENT & CSO | Sale | 2,663 | $11.90 | $31,676.65 | filing |
| 2026-03-03 | Eckert Celia· SVP, GENERAL COUNSEL | Sale | 1,492 | $11.90 | $17,747.49 | filing |
| 2026-03-02 | Desjarlais John R· SR. VICE PRESIDENT & CSO | Award | 24,907 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.